Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Lisa Evans DeWald"'
Autor:
Demetrius Matassov, Lisa Evans DeWald, Stefan Hamm, Rebecca M. Nowak, Cheryl S. Gerardi, Theresa E. Latham, Rong Xu, Amara Luckay, Tracy Chen, Marc Tremblay, Jeffry Shearer, Melissa Wynn, John H. Eldridge, Kelly Warfield, Kevin Spurgers
Publikováno v:
Vaccines, Vol 12, Iss 8, p 858 (2024)
There are currently no prophylactic vaccines licensed to protect against Lassa fever caused by Lassa virus (LASV) infection. The Emergent BioSolutions (EBS) vaccine candidate, EBS-LASV, is being developed for the prevention of Lassa fever. EBS-LASV i
Externí odkaz:
https://doaj.org/article/5ac6e9310ddd44a58999bee90fd7b27a
Autor:
Michael Callahan, Anthony M Treston, Grace Lin, Marla Smith, Brian Kaufman, Mansoora Khaliq, Lisa Evans DeWald, Kevin Spurgers, Kelly L Warfield, Preeya Lowe, Matthew Duchars, Aruna Sampath, Urban Ramstedt
Publikováno v:
PLoS Neglected Tropical Diseases, Vol 16, Iss 8, p e0010636 (2022)
BackgroundUV-4 (N-(9'-methoxynonyl)-1-deoxynojirimycin, also called MON-DNJ) is an iminosugar small-molecule oral drug candidate with in vitro antiviral activity against diverse viruses including dengue, influenza, and filoviruses and demonstrated in
Externí odkaz:
https://doaj.org/article/1b9a38644e1447e182ac97752d59a1a1
Autor:
Emily Speranza, Ignacio Caballero, Anna N. Honko, Joshua C. Johnson, J. Kyle Bohannon, Lisa Evans DeWald, Dawn M. Gerhardt, Jennifer Sword, Lisa E. Hensley, Richard S. Bennett, John H. Connor
Publikováno v:
mBio, Vol 11, Iss 3 (2020)
ABSTRACT Outbreaks of filoviruses, such as those caused by the Ebola (EBOV) and Marburg (MARV) virus, are difficult to detect and control. The initial clinical symptoms of these diseases are nonspecific and can mimic other endemic pathogens. This mak
Externí odkaz:
https://doaj.org/article/585f2770b00e43a7b83cec4c20ac4e4e
Autor:
Evelyn M Covés-Datson, Julie Dyall, Lisa Evans DeWald, Steven R King, Derek Dube, Maureen Legendre, Elizabeth Nelson, Kelly C Drews, Robin Gross, Dawn M Gerhardt, Lisa Torzewski, Elena Postnikova, Janie Y Liang, Bhupal Ban, Jagathpala Shetty, Lisa E Hensley, Peter B Jahrling, Gene G Olinger, Judith M White, David M Markovitz
Publikováno v:
PLoS Neglected Tropical Diseases, Vol 13, Iss 7, p e0007595 (2019)
Ebolaviruses cause an often rapidly fatal syndrome known as Ebola virus disease (EVD), with average case fatality rates of ~50%. There is no licensed vaccine or treatment for EVD, underscoring the urgent need to develop new anti-ebolavirus agents, es
Externí odkaz:
https://doaj.org/article/be3daa2799a548df9e5ee6400d5ad727
Autor:
Courtney L. Finch, Julie Dyall, Shuang Xu, Elizabeth A. Nelson, Elena Postnikova, Janie Y. Liang, Huanying Zhou, Lisa Evans DeWald, Craig J. Thomas, Amy Wang, Xin Xu, Emma Hughes, Patrick J. Morris, Jon C. Mirsalis, Linh H. Nguyen, Maria P. Arolfo, Bryan Koci, Michael R. Holbrook, Lisa E. Hensley, Peter B. Jahrling, Connie Schmaljohn, Lisa M. Johansen, Gene G. Olinger, Joshua T. Schiffer, Judith M. White
Publikováno v:
Microorganisms, Vol 9, Iss 3, p 566 (2021)
Outbreaks of Ebola ebolavirus (EBOV) have been associated with high morbidity and mortality. Milestones have been reached recently in the management of EBOV disease (EVD) with licensure of an EBOV vaccine and two monoclonal antibody therapies. Howeve
Externí odkaz:
https://doaj.org/article/82de7543d8574e21bfe1a76eb2884bfa
Autor:
Elena Postnikova, Yu Cong, Lisa Evans DeWald, Julie Dyall, Shuiqing Yu, Brit J Hart, Huanying Zhou, Robin Gross, James Logue, Yingyun Cai, Nicole Deiuliis, Julia Michelotti, Anna N Honko, Richard S Bennett, Michael R Holbrook, Gene G Olinger, Lisa E Hensley, Peter B Jahrling
Publikováno v:
PLoS ONE, Vol 13, Iss 3, p e0194880 (2018)
Identifying effective antivirals for treating Ebola virus disease (EVD) and minimizing transmission of such disease is critical. A variety of cell-based assays have been developed for evaluating compounds for activity against Ebola virus. However, ve
Externí odkaz:
https://doaj.org/article/b7073771bcb34e73930d7a2a00ff3b23
Autor:
Elizabeth A Nelson, Julie Dyall, Thomas Hoenen, Alyson B Barnes, Huanying Zhou, Janie Y Liang, Julia Michelotti, William H Dewey, Lisa Evans DeWald, Richard S Bennett, Patrick J Morris, Rajarshi Guha, Carleen Klumpp-Thomas, Crystal McKnight, Yu-Chi Chen, Xin Xu, Amy Wang, Emma Hughes, Scott Martin, Craig Thomas, Peter B Jahrling, Lisa E Hensley, Gene G Olinger, Judith M White
Publikováno v:
PLoS Neglected Tropical Diseases, Vol 11, Iss 4, p e0005540 (2017)
Phosphatidylinositol-3-phosphate 5-kinase (PIKfyve) is a lipid kinase involved in endosome maturation that emerged from a haploid genetic screen as being required for Ebola virus (EBOV) infection. Here we analyzed the effects of apilimod, a PIKfyve i
Externí odkaz:
https://doaj.org/article/19a1dce2d6914c7dbc9521614d84c222
Autor:
Yíngyún Caì, Masaharu Iwasaki, Brett F. Beitzel, Shuīqìng Yú, Elena N. Postnikova, Beatrice Cubitt, Lisa Evans DeWald, Sheli R. Radoshitzky, Laura Bollinger, Peter B. Jahrling, Gustavo F. Palacios, Juan C. de la Torre, Jens H. Kuhn
Publikováno v:
Viruses, Vol 10, Iss 11, p 655 (2018)
Lassa virus (LASV), a mammarenavirus, infects an estimated 100,000⁻300,000 individuals yearly in western Africa and frequently causes lethal disease. Currently, no LASV-specific antivirals or vaccines are commercially available for prevention or tr
Externí odkaz:
https://doaj.org/article/cff65530011244159414a272e7224567
Autor:
Yu Cong, Julie Dyall, Brit J Hart, Lisa Evans DeWald, Joshua C Johnson, Elena Postnikova, Huanying Zhou, Robin Gross, Oscar Rojas, Isis Alexander, Nicole Josleyn, Tengfei Zhang, Julia Michelotti, Krisztina Janosko, Pamela J Glass, Mike Flint, Laura K McMullan, Christina F Spiropoulou, Tim Mierzwa, Rajarshi Guha, Paul Shinn, Sam Michael, Carleen Klumpp-Thomas, Crystal McKnight, Craig Thomas, Ann E Eakin, Kathleen G O'Loughlin, Carol E Green, Paul Catz, Jon C Mirsalis, Anna N Honko, Gene G Olinger, Richard S Bennett, Michael R Holbrook, Lisa E Hensley, Peter B Jahrling
Publikováno v:
PLoS ONE, Vol 11, Iss 11, p e0166318 (2016)
In the fall of 2014, an international news agency reported that patients suffering from Ebola virus disease (EVD) in Liberia were treated successfully with lamivudine, an antiviral drug used to treat human immunodeficiency virus-1 and hepatitis B vir
Externí odkaz:
https://doaj.org/article/46cb98f2678f4277aab2f35637509fbf
Autor:
Michael Callahan, Anthony M. Treston, Grace Lin, Marla Smith, Brian Kaufman, Mansoora Khaliq, Lisa Evans DeWald, Kevin Spurgers, Kelly L. Warfield, Preeya Lowe, Matthew Duchars, Aruna Sampath, Urban Ramstedt
Publikováno v:
PLoS neglected tropical diseases. 16(8)
Background UV-4 (N-(9’-methoxynonyl)-1-deoxynojirimycin, also called MON-DNJ) is an iminosugar small-molecule oral drug candidate with in vitro antiviral activity against diverse viruses including dengue, influenza, and filoviruses and demonstrated